KHRNF - Khiron Life Sciences Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
1.3600
-0.0772 (-5.37%)
At close: 3:58PM EDT
Stock chart is not supported by your current browser
Previous Close1.4372
Open1.4000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.3500 - 1.4000
52 Week Range0.6837 - 3.2800
Volume243,789
Avg. Volume157,054
Market Cap142.805M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.3020
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Khiron Provides Progress Update on Fully Operational and GMP Compliant Colombian Lab Facilities
    PR Newswire

    Khiron Provides Progress Update on Fully Operational and GMP Compliant Colombian Lab Facilities

    State-of-the-art, 14,000 square foot GMP compliant cannabis extraction lab and ISO 17025 compliant cannabis testing lab includes full capabilities in Ultra high and High performance liquid chromatography ...

  • CNW Group

    Khiron Announces DTC Eligibility, Increasing Access for U.S. Investors

    TORONTO , Aug. 20, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (KHRNF), (Frankfurt:A2JMZC), an integrated cannabis company with core operations in Latin America, announced today that its shares have received Depository Trust Company (DTC) full-service eligibility in the United States . DTC eligibility is expected to simplify the process of trading and transferring of the Company's common shares in the United States .

  • PR Newswire

    Khiron Provides Clarification of August 12, 2019 News Release

    TORONTO, Aug. 14, 2019 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt: A2JMZC), an integrated cannabis company with core operations in Latin America, wishes to clarify specific disclosure relating to the news release disseminated by the Company on August 12, 2019. Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America. Khiron has core operations in Latin America and is fully licensed in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis.

  • PR Newswire

    Khiron Boosts European Expansion With Key Executive Appointments

    Experienced capital markets leader and cannabis industry executive Tejinder Virk is appointed President of Khiron Europe Accomplished cannabis legal expert Franziska Katterbach joins Company as Chief Legal ...

  • CNW Group

    Khiron Launches Revenue-Generating Pilot Program With Top Colombian Health Insurance Provider

    Khiron Launches Revenue-Generating Pilot Program With Top Colombian Health Insurance Provider

  • CNW Group

    Khiron Signs Kuida Distribution Agreement with Grupo Éxito, South America's Market Leading Retail Group

    Grupo Éxito has a multinational retail presence in Colombia , Brazil , Argentina and Uruguay and operates 1,533 stores. Kuida to be introduced as key addition to the retailer's cosmetics products category, with experience centres and consultants in each Éxito WOW store to support sales and brand awareness.

  • Khiron and Dixie Receive Conditional TSXV Approval for Roll-Out of Kuida Cosmeceutical Line in U.S. Market and Cannabis-Infused Products in Latin America
    CNW Group

    Khiron and Dixie Receive Conditional TSXV Approval for Roll-Out of Kuida Cosmeceutical Line in U.S. Market and Cannabis-Infused Products in Latin America

    Khiron and Dixie Receive Conditional TSXV Approval for Roll-Out of Kuida Cosmeceutical Line in U.S. Market and Cannabis-Infused Products in Latin America

  • CNW Group

    Khiron Provides Update on Canapalife Group Transaction

    TORONTO , Aug. 1, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt:A2JMZC), an integrated cannabis company with core operations in Latin America, today provided an update on the Company's previously announced non-binding LOI with Canapalife Group. The Company confirms the expiry of the LOI and that the parties have mutually agreed not to proceed with the proposed transaction. Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America.

  • PR Newswire

    Khiron Begins Pre-clinical Medical Cannabis Studies with Leading Academic Institutes in Uruguay

    Patient-focused studies advance progress towards global clinical trials on Khiron strains to treat inflammation, oxidative and nervous system disorders Co-sponsored with Uruguay government using Company ...

  • PR Newswire

    Khiron Announces Final Approval of Acquisition of NettaGrowth

    TORONTO, July 30, 2019 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt: A2JMZC), a medical cannabis company with core operations in Latin America, reports that the Company has received final approval from the TSX Venture Exchange ("TSXV") to close its previously announced acquisition (the "Acquisition") of NettaGrowth International Inc. ("NettaGrowth"), which owns all of the outstanding shares of a Uruguayan company, Dormul S.A. ("Dormul"). As consideration for the Acquisition, Khiron issued 8,498,821 common shares to the shareholders of NettaGrowth, at a deemed price of $1.61 per common share.

  • PR Newswire

    Khiron Life Sciences Added to NYSE-Listed The Cannabis ETF

    TORONTO, July 25, 2019 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (KHRNF), (Frankfurt: A2JMZC), an integrated cannabis company with core operations in Latin America, announced today that it has been added to The Cannabis ETF (NYSE:THCX) ("THCX"), which trades on the New York Stock Exchange. Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America.

  • Benzinga

    From Coffee To Cannabis: Colombia's Choice Between Economic Development And 'CannaMercantilism'

    This is the second of a two-part series on the history of Colombia’s troubled past and how it has informed its route to cannabis legalization. Mr. Azadian replied, “We were frustrated with many things in the marketplace including product inconsistency, quality control standards, inefficiencies, high costs of products and environmentally unsustainable operations.

  • CNW Group

    Khiron Obtains Final Approval to Commercialize CBD Production and Receives Approval for an additional 17 Cannabis Strains from Colombian Agricultural Institute

    Khiron has now secured all approvals required to commercialize current CBD cultivation and production for medical purposes. Khiron has now registered a total of 22 strains with Colombian Agricultural Institute ("ICA"). TORONTO , July 17, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt:A2JMZC), a vertically integrated cannabis leader with core operations in Latin America , announced today that it has received approval from the National Cultivar Registry and the Technical Direction of the ICA for the commercialization of 17 stains of cannabis.